vs
Side-by-side financial comparison of R F INDUSTRIES LTD (RFIL) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
ZEVRA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($34.1M vs $22.7M, roughly 1.5× R F INDUSTRIES LTD). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs 22.9%). ZEVRA THERAPEUTICS, INC. produced more free cash flow last quarter ($5.5M vs $2.0M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs 29.8%).
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
RFIL vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.7M | $34.1M |
| Net Profit | $173.0K | — |
| Gross Margin | 36.8% | — |
| Operating Margin | 4.0% | 27.3% |
| Net Margin | 0.8% | — |
| Revenue YoY | 22.9% | 183.4% |
| Net Profit YoY | 172.7% | — |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.7M | $34.1M | ||
| Q3 25 | $19.8M | $26.1M | ||
| Q2 25 | $18.9M | $25.9M | ||
| Q1 25 | $19.2M | $20.4M | ||
| Q4 24 | $18.5M | $12.0M | ||
| Q3 24 | $16.8M | $3.7M | ||
| Q2 24 | $16.1M | $4.4M | ||
| Q1 24 | $13.5M | $3.4M |
| Q4 25 | $173.0K | — | ||
| Q3 25 | $392.0K | $-544.0K | ||
| Q2 25 | $-245.0K | $74.7M | ||
| Q1 25 | $-245.0K | $-3.1M | ||
| Q4 24 | $-238.0K | — | ||
| Q3 24 | $-705.0K | $-33.2M | ||
| Q2 24 | $-4.3M | $-19.9M | ||
| Q1 24 | $-1.4M | $-16.6M |
| Q4 25 | 36.8% | — | ||
| Q3 25 | 34.0% | — | ||
| Q2 25 | 31.5% | — | ||
| Q1 25 | 29.8% | — | ||
| Q4 24 | 31.3% | — | ||
| Q3 24 | 29.5% | — | ||
| Q2 24 | 29.9% | — | ||
| Q1 24 | 24.5% | — |
| Q4 25 | 4.0% | 27.3% | ||
| Q3 25 | 3.6% | 15.9% | ||
| Q2 25 | 0.6% | -274.5% | ||
| Q1 25 | 0.3% | -26.3% | ||
| Q4 24 | 0.5% | -128.0% | ||
| Q3 24 | -2.5% | -739.0% | ||
| Q2 24 | -2.6% | -534.8% | ||
| Q1 24 | -15.5% | -598.1% |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 2.0% | -2.1% | ||
| Q2 25 | -1.3% | 288.7% | ||
| Q1 25 | -1.3% | -15.2% | ||
| Q4 24 | -1.3% | — | ||
| Q3 24 | -4.2% | -899.2% | ||
| Q2 24 | -26.7% | -447.9% | ||
| Q1 24 | -10.1% | -485.3% |
| Q4 25 | $0.01 | — | ||
| Q3 25 | $0.04 | $-0.01 | ||
| Q2 25 | $-0.02 | $1.21 | ||
| Q1 25 | $-0.02 | — | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.07 | $-0.69 | ||
| Q2 24 | $-0.41 | $-0.48 | ||
| Q1 24 | $-0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $35.2M | $154.7M |
| Total Assets | $73.0M | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $62.4M | ||
| Q3 25 | $3.0M | $54.4M | ||
| Q2 25 | $3.6M | $47.7M | ||
| Q1 25 | $1.3M | $37.3M | ||
| Q4 24 | $839.0K | $33.8M | ||
| Q3 24 | $1.8M | $54.0M | ||
| Q2 24 | $1.4M | $39.3M | ||
| Q1 24 | $4.5M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $35.2M | $154.7M | ||
| Q3 25 | $34.8M | $133.2M | ||
| Q2 25 | $34.2M | $117.2M | ||
| Q1 25 | $34.2M | $41.0M | ||
| Q4 24 | $34.1M | $39.7M | ||
| Q3 24 | $34.1M | $69.8M | ||
| Q2 24 | $34.6M | $32.5M | ||
| Q1 24 | $38.7M | $48.8M |
| Q4 25 | $73.0M | $284.7M | ||
| Q3 25 | $73.2M | $270.1M | ||
| Q2 25 | $72.7M | $256.3M | ||
| Q1 25 | $70.4M | $172.7M | ||
| Q4 24 | $71.0M | $178.1M | ||
| Q3 24 | $71.9M | $191.6M | ||
| Q2 24 | $72.8M | $144.4M | ||
| Q1 24 | $79.1M | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $5.5M |
| Free Cash FlowOCF − Capex | $2.0M | $5.5M |
| FCF MarginFCF / Revenue | 9.0% | 16.1% |
| Capex IntensityCapex / Revenue | 0.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 12.13× | — |
| TTM Free Cash FlowTrailing 4 quarters | $4.3M | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $5.5M | ||
| Q3 25 | $-311.0K | $4.7M | ||
| Q2 25 | $2.2M | $-3.6M | ||
| Q1 25 | $601.0K | $-8.2M | ||
| Q4 24 | $-244.0K | $-16.3M | ||
| Q3 24 | $2.4M | $-18.1M | ||
| Q2 24 | $197.0K | $-19.1M | ||
| Q1 24 | $840.0K | $-16.2M |
| Q4 25 | $2.0M | $5.5M | ||
| Q3 25 | $-419.0K | $4.2M | ||
| Q2 25 | $2.2M | $-3.8M | ||
| Q1 25 | $574.0K | $-8.3M | ||
| Q4 24 | $-418.0K | — | ||
| Q3 24 | $2.1M | — | ||
| Q2 24 | $28.0K | — | ||
| Q1 24 | $697.0K | — |
| Q4 25 | 9.0% | 16.1% | ||
| Q3 25 | -2.1% | 15.9% | ||
| Q2 25 | 11.4% | -14.7% | ||
| Q1 25 | 3.0% | -40.8% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 5.2% | — |
| Q4 25 | 0.3% | 0.1% | ||
| Q3 25 | 0.5% | 2.1% | ||
| Q2 25 | 0.2% | 0.8% | ||
| Q1 25 | 0.1% | 0.5% | ||
| Q4 24 | 0.9% | 0.0% | ||
| Q3 24 | 1.5% | 0.0% | ||
| Q2 24 | 1.0% | 0.0% | ||
| Q1 24 | 1.1% | 0.0% |
| Q4 25 | 12.13× | — | ||
| Q3 25 | -0.79× | — | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RFIL
| US | $20.9M | 92% |
| Non Us | $1.8M | 8% |
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
